Oncology


Unlocking Innovative Strategies in the Management of Extensive-Stage Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is an aggressive form of the disease that comprises 15% of all new lung cancer cases diagnosed each year. This type of lung cancer tends to grow and spread faster than NSCLC. About 70% of people with SCLC will have cancer that has already spread at the time they are diagnosed. Outcomes for patients with SCLC are poor with a median survival of less than 1 year. Small cell lung cancer is a disease with limited treatment options, presenting a strong unmet need, especially for patients with relapsed disease. Fortunately for patients with SCLC, there are emerging options with novel mechanisms of action showing great promise in clinical trials, including B7-H3–targeted antibody drug conjugates (ADCs). With so much evolution in the treatment paradigm over recent years, it is critical that physician medical directors, oncologists, nurse case managers and other healthcare professionals are brought up to date on these emerging options and the role that they play in improving both clinical and economic outcomes in various settings of SCLC.
Physician, Nursing and CMCN credits valid to August 1, 2027

Recent Advances in the Treatment and Management of Non-Small Cell Lung Cancer

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2024, it is expected that there were approximately 238,340 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 127,070 deaths from lung cancer in 2024, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. Fortunately for patients with NSCLC, several new treatments have recently become available or are in regulatory review for HER2-mutant unresectable or metastatic NSCLC, including tyrosine kinase inhibitors (TKIs) that selectively inhibits HER2 (ERBB2) while sparing EGFR, giving clinicians new options to improve clinical and economic outcomes. Healthcare professionals (HCPs) need to be aware of information regarding recent clinical trial data and regulatory decisions, integration strategies, managed care considerations, and supporting data to maximize the care of their patients. With so many effective treatment options coming now and in the near future, it is critical to inform medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.
Physician, Nursing and CMCN credits valid to August 1, 2027

Keeping Pace with Rapid Advancements in the Management of Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. The American Cancer Society estimates that there were approximately 20,050 new cases of AML and 11,540 deaths from AML in the United States in 2023. Fortunately for patients with AML, many new treatments that have shown improved efficacy and safety have been approved recently, especially in patients with specific mutations such as IDH1/2 and FLT3. With so many new options becoming available in the past few years, and more to come, the treatment paradigm in AML has drastically changed. With that change comes a knowledge gap among physician medical directors, oncologists, practicing physicians and nurses. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the AML patient population.
Physician, Nursing and CMCN credits valid to August 1, 2027

Optimal Therapeutic Approaches in Bladder Cancer: Improving Patient Outcomes through Novel Therapies and Combinations

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there were an estimated 82,290 new cases of bladder cancer and 17,100 deaths in the United States in 2024. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, and when patients are ineligible for cisplatin-containing chemotherapy, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents, including gene therapies, have recently emerged for patients with metastatic bladder cancer, especially in patients who are ineligible for cisplatin-containing chemotherapy.
Physician, Nursing and CMCN credits valid to August 1, 2027

Unlocking Innovative Approaches in the Treatment and Management of HR+/HER2- Breast Cancer

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2025. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease- and treatment-related adverse events. Fortunately for patients with HR+/HER2- advanced breast cancer, several new agents, including oral SERDs, have recently been approved or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes in the approximately 40% of patients living with HR+/HER2- advanced breast cancer, especially in those whose breast cancer harbors an ESR1 gene mutation. With these options becoming available for the treatment of metastatic breast cancer, and clinical data being recently presented, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on these new therapies changing the treatment paradigm, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Unlocking Innovative Strategies in the Treatment and Management of Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2024, it is expected that there were 20,160 new cases of CLL and about 4,410 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available, including BTK inhibitors, giving clinicians many new options to improve patient outcomes with these new treatments and strategies. Additionally, noncovalent BTK inhibitors have recently become available, giving managed care professionals even more options to improve outcomes for patients with CLL. This activity focuses on these evolving options and outlines how to incorporate quality measures for the diagnosis and management of CLL and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities. With the availability of new treatments, it is critical that physician medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging options, guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Keeping Pace with Rapid Advancements in the Management of dMMR/MSI-H Colorectal Cancer: Leveraging Immunotherapy for Improved Clinical and Economic Outcomes

Colorectal cancer (CRC) is the development of cancer from the colon or rectum (parts of the large intestine). It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. In 2024, it was expected that there were 134,490 new cases of colorectal cancer and 49,190 deaths. Colorectal cancer, when discovered early, is highly treatable. However, when the disease has spread, or metastasized, treatment and management becomes much more difficult. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. Fortunately for patients with advanced colorectal cancer, new and emerging immunotherapies, including PD-1 inhibitors, have come to the forefront of management in recent years, with more coming in the near future, giving managed care professionals and clinicians more options for treating these patients, especially in tumors with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) disease. With so many new therapies now and on the horizon entering the treatment paradigm, knowledge gaps have been created, making imperative that managed care physician medical directors, oncologists, pharmacists, payers, nurses and other healthcare professionals who manage colorectal cancer patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Informed Managed Care Decision Making in the Management of Endometrial Cancer: A Closer Look at the Evolving Role of Immunotherapy for Optimized Access and Outcomes

Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States. The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age. There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. Fortunately for patients with endometrial cancer, new and emerging therapies and combinations, including immune based therapies such as PD-1 Inhibitors, having recently been approved, giving managed care professionals and clinicians more options for treating this patient population. With so many new therapies entering the treatment paradigm knowledge gaps have been created, making imperative that managed care physician medical directors, oncologists, pharmacists, payers, nurses and other healthcare professionals who manage EC patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Informed Managed Care Decision-Making in the First-Line Management of HER2-Positive Metastatic Breast Cancer: Applying the Latest Evidence to Improve Outcomes

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 313,510 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2025. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. Additionally, in the later stages of HER2+ disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the HER2+ metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life.
Fortunately for patients with HER2-positive advanced breast cancer, several new options have recently undergone practice changing clinical trials. They have shown the ability to improve safety and efficacy outcomes in patients living with HER2-positive advanced breast cancer, especially recently in the first-line setting. With these options entering the treatment paradigm, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on these new therapies the changing treatment paradigm, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Innovative Approaches in the Treatment and Management of Metastatic Triple-Negative Breast Cancer (TNBC): Managed Care Considerations on the Evolving Role of Antibody Drug Conjugates

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2025. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life.
Fortunately for patients with metastatic triple-negative breast cancer, several new agents, including TROP-2 directed antibody drug conjugates (ADCs), have recently become available or have completed late stage clinical trials, giving clinicians and managed care professionals another important option in managing these patients. These new therapies have shown the ability to improve safety and efficacy outcomes and potentially change practice in the approximately 15% of patients living with metastatic triple-negative breast cancer. With these options becoming available now and in the near future for the treatment of metastatic triple-negative breast cancer, especially for the 70% of these patients who are not candidates for immunotherapy, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on these new ADC therapies changing the treatment paradigm, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Evolving Strategies in the Treatment and Management of Multiple Myeloma

Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2025, it is estimated that MM will be responsible for 12,590 new deaths and 35,730 new cases. Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 months to 30 months and a 10-year survival of 3%. There are several novel options for relapsed or refractory multiple myeloma that have shown great promise in their ability to improve clinical outcomes, including options that have recently completed or are undergoing clinical trials. It is important that medical directors, oncologists, nurse case managers and other healthcare professionals are brought up to date on these new and emerging therapies and how these options can be integrated into evolving treatment paradigms in the management of relapsed/refractory multiple myeloma treatment.
Physician, Nursing and CMCN credits valid to August 1, 2027

Evolving Considerations in the Treatment and Management of Ovarian Cancer

There were an estimated 19,880 new cases of ovarian cancer last year in the United States, and an estimated 12,810 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. With these new options on the horizon, it is imperative to educate physician medical directors, oncologists, pharmacy directors, nurses and other healthcare professionals on these emerging treatments and strategies for patients who would benefit from these novel options, ultimately improving clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2027

Integrating Novel Therapies into Bladder Cancer Care: How Groundbreaking Therapies Can Advance Patient Outcomes

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there were an estimated 82,290 new cases of bladder cancer and 17,100 deaths in the United States in 2024. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, and when patients are ineligible for cisplatin-containing chemotherapy, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents have recently emerged for patients with metastatic bladder cancer, especially in patients who have non-muscle-invasive bladder cancer. Ultimately healthcare professionals need to be educated on the newly approved therapeutic strategies in their management of early bladder cancer and their ability to improve both clinical and economic outcomes and quality of life in patients.
Physician, Nursing and CMCN credits valid to March 1, 2027

Innovative Approaches in the Treatment and Management of HR+/HER2- Metastatic Breast Cancer

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2025. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Fortunately for patients with HR+/HER2- advanced breast cancer, several new agents, including oral SERDs, have recently undergone clinical trials or are undergoing regulatory review. They have shown the ability to improve safety and efficacy outcomes in the approximately 40% of patients living with HR+/HER2- advanced breast cancer, especially in those whose breast cancer harbors an ESR1 gene mutation. With these options becoming available for the treatment of metastatic breast cancer, and real world data being recently presented, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical data and strategies on these new therapies and changing treatment paradigm, with the ultimate goal of improving patient outcomes.
Physician, Nursing and CMCN credits valid to March 1, 2027

Overcoming Barriers to the Optimal Treatment and Management of Endometrial Cancer: Leveraging Immunotherapy for Improved Clinical and Economic Outcomes

Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States. The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage cancers, high-risk histologies, and patients being diagnosed at an older age. There are significant disparities between White and Black women regarding rates of early-stage diagnosis (75% vs 62%) and 5-year relative survival (84% vs 63%). When patients are diagnosed with distant-stage disease, 5-year relative survival rates plummet to 18% for all races. Early identification of high-risk patients and personalized treatment approaches for this complex, multifaceted disease are needed to improve outcomes. Fortunately for patients with endometrial cancer, new and emerging therapies, including immune based therapies such as PD-1 Inhibitors, have recently been approved, giving managed care professionals and clinicians more options for treating this patient population. With so many new therapies entering the treatment paradigm, knowledge gaps have been created, making it imperative that managed care physician medical directors, oncologists, pharmacists, payers, nurses and other healthcare professionals who manage EC patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.
Physician, Nursing and CMCN credits valid to March 1, 2027

Evolving Considerations in the Treatment and Management of Mantle Cell Lymphoma (MCL): A Closer Look at the Role of BTK Inhibitors for Improved Outcomes

Mantle cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone.” The mantle zone is the outer ring of small lymphocytes surrounding the center of a lymphatic nodule. MCL accounts for roughly six percent of all NHL cases in the United States. Frequently, mantle cell lymphoma is diagnosed at a later stage of disease and in most cases involves the gastrointestinal tract and bone marrow, which makes treatment more difficult. Fortunately for patients with MCL, several new treatments have recently become available, including BTK inhibitors, giving clinicians many new options to improve patient outcomes with these new treatments and strategies. Additionally, combination options with BTK inhibitors are emerging as effective treatment options, especially in front-line MCL. This activity focuses on these evolving options and their combinations, outlines how to incorporate quality measures for the diagnosis and management of MCL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities. With the availability of new treatments, it is critical that medical directors, oncologists, nurses, and other healthcare professionals are updated on these emerging options, guidelines, and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to March 1, 2027

Keeping Pace with Rapid Advancements in the Treatment and Management of Multiple Myeloma: Expert Perspectives on the Impact of BCMA-Directed Therapy

Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2025, it is estimated that MM will be responsible for 12,590 new deaths and 35,730 new cases. Multiple myeloma is a systemic malignancy of plasma cells that is highly treatable but rarely curable. It is potentially curable when it presents as a solitary plasmacytoma of bone or as an extramedullary plasmacytoma. The median survival in the prechemotherapy era was about 7 months. After the introduction of chemotherapy, prognosis improved significantly with a median survival of 24 months to 30 months and a 10-year survival of 3%. There are several novel options for relapsed or refractory multiple myeloma that have shown great promise in their ability to improve clinical outcomes, including options that have recently completed or are undergoing clinical trials. It is important that medical directors, oncologists, nurse case managers and other healthcare professionals are brought up to date on these new and emerging therapies and how these options can be integrated into evolving treatment paradigms in the management of relapsed/refractory multiple myeloma treatment.
Physician, Nursing and CMCN credits valid to March 1, 2027

Innovative Approaches in the Treatment and Management of Non-Small Cell Lung Cancer

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2024, it is expected that there were approximately 238,340 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 127,070 deaths from lung cancer in 2024, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. Fortunately for patients with NSCLC, several new treatments have recently become available or are in regulatory review for HER2-mutant unresectable or metastatic NSCLC, including tyrosine kinase inhibitors (TKIs) that selectively inhibits HER2 (ERBB2) while sparing EGFR, giving clinicians new options to improve clinical and economic outcomes. Healthcare professionals (HCPs) need to be aware of information regarding recent clinical trial data and regulatory decisions, integration strategies, managed care considerations, and supporting data to maximize the care of their patients. With so many effective treatment options coming now and in the near future, it is critical to inform medical directors, oncologists, and nurses about these agents and strategies to effectively manage NSCLC patients.
Physician, Nursing and CMCN credits valid to March 1, 2027

Informed Managed Care Decision-Making in the Treatment and Management of Ovarian Cancer: Optimizing Clinical and Economic Outcomes in an Evolving Paradigm

There were an estimated 19,880 new cases of ovarian cancer and an estimated 12,810 deaths due to ovarian cancer in the US last year, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in maintenance in the first-line setting. It is important for medical directors, oncologists, and nurses who manage ovarian cancer patient populations to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.
Physician, Nursing and CMCN credits valid to March 1, 2027

Novel Treatment Advances and Approaches in the Management of Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is an aggressive form of the disease that comprises 15% of all new lung cancer cases diagnosed each year. This type of lung cancer tends to grow and spread faster than NSCLC. About 70% of people with SCLC will have cancer that has already spread at the time they are diagnosed. Outcomes for patients with SCLC are poor with a median survival of less than 1 year. Small cell lung cancer is a disease with limited treatment options, presenting a strong unmet need, especially for patients with relapsed disease. Fortunately for patients with SCLC, there are emerging options with novel mechanisms of action showing great promise in clinical trials, including B7-H3–targeted antibody drug conjugates (ADCs). With so much evolution in the treatment paradigm over recent years, it is critical that physician medical directors, oncologists, nurse case managers and other healthcare professionals are brought up to date on these emerging options and the role that they play in improving both clinical and economic outcomes in various settings of SCLC.
Physician, Nursing and CMCN credits valid to March 1, 2027

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.

Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.